Inflammation promotes regeneration of injured tissues through poorly understood mechanisms, some of which involve interleukin (IL)-6 family members, the expression of which is elevated in many diseases including inflammatory bowel diseases and colorectal cancer. Here we show in mice and human cells that gp130, a co-receptor for IL-6 cytokines, triggers activation of YAP and Notch, transcriptional regulators that control tissue growth and regeneration, independently of the gp130 effector STAT3. Through YAP and Notch, intestinal gp130 signalling stimulates epithelial cell proliferation, causes aberrant differentiation and confers resistance to mucosal erosion. gp130 associates with the related tyrosine kinases Src and Yes, which are activated on receptor engagement to phosphorylate YAP and induce its stabilization and nuclear translocation. This signalling module is strongly activated upon mucosal injury to promote healing and maintain barrier function.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


Primary accessions


Data deposits

Microarray data reported here have been deposited in the ArrayExpress database under accession E-MEXP-E-MTAB-2400.


  1. 1.

    & Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunol. 12, 715–723 (2011)

  2. 2.

    Origin and physiological roles of inflammation. Nature 454, 428–435 (2008)

  3. 3.

    , & Organ repair and regeneration: an overview. Birth Defects Res. C 96, 1–29 (2012)

  4. 4.

    & The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature Rev. Drug Discov. 13, 63–79 (2014)

  5. 5.

    , & Immunity, inflammation, and cancer. Cell 140, 883–899 (2010)

  6. 6.

    New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 7, 6–19 (2014)

  7. 7.

    et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 23, 85–97 (2012)

  8. 8.

    IL-6: from its discovery to clinical applications. Int. Immunol. 22, 347–352 (2010)

  9. 9.

    , & SOCS proteins, cytokine signalling and immune regulation. Nature Rev. Immunol. 7, 454–465 (2007)

  10. 10.

    & More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88, 1109–1117 (2010)

  11. 11.

    , , , & Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr. Pharm. Des. 15, 2095–2103 (2009)

  12. 12.

    et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 208, 1359–1366 (2011)

  13. 13.

    et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103–113 (2009)

  14. 14.

    et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200–204 (2009)

  15. 15.

    , & Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199–219 (2012)

  16. 16.

    et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24, 2383–2388 (2010)

  17. 17.

    et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G23–G35 (2009)

  18. 18.

    & The Hippo pathway: regulators and regulations. Genes Dev. 27, 355–371 (2013)

  19. 19.

    et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457–1473 (2012)

  20. 20.

    Notch signalling: a simple pathway becomes complex. Nature Rev. Mol. Cell Biol. 7, 678–689 (2006)

  21. 21.

    et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277, 33275–33283 (2002)

  22. 22.

    et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 17, 2054–2060 (2007)

  23. 23.

    et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc. Natl Acad. Sci. USA 108, E1312–E1320 (2011)

  24. 24.

    et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435, 964–968 (2005)

  25. 25.

    et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963 (2005)

  26. 26.

    & Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340, 1190–1194 (2013)

  27. 27.

    et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415–418 (2011)

  28. 28.

    et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22, 1511–1516 (2003)

  29. 29.

    et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biol. 11 1444–1450 10.1038/ncb1993 (2009)

  30. 30.

    et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398–410 (2009)

  31. 31.

    , , , & The role of Src in colon cancer and its therapeutic implications. Clin. Colorectal Cancer 13, 5–13 (2014)

  32. 32.

    , , & Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell 29, 350–361 (2008)

  33. 33.

    et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 158, 157–170 (2014)

  34. 34.

    Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9, 2145–2152 (1994)

  35. 35.

    et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev. Cell 26, 658–665 (2013)

  36. 36.

    et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144, 1530–1542 (2013)

  37. 37.

    , , , & Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and hippo pathway effectors by Notch1. Stem Cells 30, 741–752 (2012)

  38. 38.

    et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780–791 (2012)

  39. 39.

    et al. The tumor suppressor gene, RASSF1A, is essential for protection against inflammation-induced injury. PLoS ONE 8, e75483 (2013)

  40. 40.

    , & Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J. Cell Sci. 124, 1136–1144 (2011)

  41. 41.

    , , , & Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Natl Acad. Sci. USA 96, 2846–2851 (1999)

  42. 42.

    & IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 26, 54–74 (2014)

  43. 43.

    et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487–497 (2009)

  44. 44.

    et al. c-Src drives intestinal regeneration and transformation. EMBO J. 33, 1474–1491 (2014)

  45. 45.

    et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39–49 (1999)

  46. 46.

    et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27–38 (2010)

  47. 47.

    et al. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nature Med. 15, 701–706 (2009)

  48. 48.

    et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 147, 173–184 (2011)

  49. 49.

    et al. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression. J. Invest. Dermatol. 128 2325–2333 10.1038/jid.2008.89 (2008)

  50. 50.

    , , & Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 8, 2430–2436 (2002)

  51. 51.

    et al. ERK activation drives intestinal tumorigenesis in Apcmin/+ mice. Nature Med. 16, 665–670 (2010)

  52. 52.

    , , , & In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 6, 880–886 (2000)

  53. 53.

    et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695–702 (2005)

  54. 54.

    et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009)

  55. 55.

    et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141, 1762–1772 (2011)

  56. 56.

    et al. Constitutive intestinal NF-κB does not trigger destructive inflammation unless accompanied by MAPK activation. J. Exp. Med. 208, 1889–1900 (2011)

  57. 57.

    et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007)

  58. 58.

    et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 20, 133–144 (2014)

  59. 59.

    & A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature Protocols 3, 1167–1170 (2008)

  60. 60.

    et al. A degenerative retinal process in HIV-associated non-infectious retinopathy. PLoS ONE 8, e74712 (2013)

Download references


We thank D. Pan and S. Akira for Yapfl/fl and Stat3fl/fl mice, respectively. We also thank D. L. Gumucio for a plasmid containing the 12.4-kb villin promoter, T. Sato, H. Clevers and Y. Hippo for protocols describing intestinal organoid culture, C. Kuo for R-spondin1-producing cells, D. Huszar for AZD1480, F. Schaper for plasmids, L. Eckmann for advice, A. Umemura, H. Nakagawa, H. Ogata, E. J. Park, G. Y. Yu, J. Font-Burgada, D. Dhar, J. Kim and E. Seki for providing liver samples, J. Zhao, T. Meerloo, Y. Jones, L. Gapuz, R. Ly, N. Varki, D. Aki, N. Hiramatsu, T. Moroishi, Y. Endo, H. Nishinakamura, A. Chang and T. Lee for technical advice and assistance, and Cell Signaling, Santa Cruz Biotechnology and GeneTex for antibodies. This work was supported by Postdoctoral Fellowship for Research Abroad and Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science, a Uehara Memorial Foundation Fellowship, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Kanae Foundation for the Promotion of Medical Science to K.T.; a traveling grant NSC-101-2918-I-006-005 and a research grant NSC-103-2320-B-006-032 by National Science Council of Taiwan to L.-W.W.; NIH R00DK088589, FCCC-Temple University Nodal grant, AACR-Landon Innovator Award in Tumor Microenvironment, and the Pew Scholar in Biomedical Sciences Program for S.I.G.; a CCFA fellowship (RFA2927) to P.R.d.J.; Croucher Foundation and China Postdoctoral Science Foundation to K.W.; by the Research Service of the Department of Veterans Affairs to S.B.H.; by the NIH and the UCSD Digestive Disease Research Center Grant to J.T.C. and W.J.S.; by the NIH EY022611 and CA132809 to K.-L.G.; and by the NIH CA118165-09 and AACR to M.K., who is an American Cancer Society Research Professor and holds the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases.

Author information


  1. Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA

    • Koji Taniguchi
    • , Li-Wha Wu
    • , Sergei I. Grivennikov
    • , Kepeng Wang
    •  & Michael Karin
  2. Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA

    • Koji Taniguchi
    • , Ian Lian
    • , Fa-Xing Yu
    • , Kun-Liang Guan
    •  & Michael Karin
  3. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan

    • Koji Taniguchi
    •  & Yoshihiko Maehara
  4. Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan

    • Koji Taniguchi
    •  & Akihiko Yoshimura
  5. Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan

    • Li-Wha Wu
  6. Fox Chase Cancer Center, Cancer Prevention and Control Program, Philadelphia, Pennsylvania 19111, USA

    • Sergei I. Grivennikov
  7. Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA

    • Petrus R. de Jong
    •  & Eyal Raz
  8. Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA

    • Ian Lian
    • , Fa-Xing Yu
    • , Kun-Liang Guan
    •  & Michael Karin
  9. Department of Biology, Lamar University, PO Box 10037, Beaumont, Texas 77710, USA

    • Ian Lian
  10. Children’s Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China

    • Fa-Xing Yu
  11. Department of Medicine, VA San Diego Healthcare System, San Diego, California 92161, USA

    • Samuel B. Ho
  12. Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA

    • Brigid S. Boland
    • , John T. Chang
    •  & William J. Sandborn
  13. Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA

    • Gary Hardiman
  14. CSRC and BIMRC, San Diego State University, San Diego, California 92182, USA

    • Gary Hardiman
  15. Japan Science and Technology Agency, CREST, Tokyo 102-0076, Japan

    • Akihiko Yoshimura
  16. Inserm, UMR 1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris 75010, France

    • Jessica Zucman-Rossi
  17. Université Paris Descartes, Labex Immuno-oncology, Sorbonne Paris Cité, Faculté de Medicine, Paris 75006, France

    • Jessica Zucman-Rossi


  1. Search for Koji Taniguchi in:

  2. Search for Li-Wha Wu in:

  3. Search for Sergei I. Grivennikov in:

  4. Search for Petrus R. de Jong in:

  5. Search for Ian Lian in:

  6. Search for Fa-Xing Yu in:

  7. Search for Kepeng Wang in:

  8. Search for Samuel B. Ho in:

  9. Search for Brigid S. Boland in:

  10. Search for John T. Chang in:

  11. Search for William J. Sandborn in:

  12. Search for Gary Hardiman in:

  13. Search for Eyal Raz in:

  14. Search for Yoshihiko Maehara in:

  15. Search for Akihiko Yoshimura in:

  16. Search for Jessica Zucman-Rossi in:

  17. Search for Kun-Liang Guan in:

  18. Search for Michael Karin in:


K.T. and M.K. conceived the project. K.T., L.-W.W., S.I.G., P.R.d.J., I.L., F.-X.Y., K.W., G.H. performed the experiments. K.T., L.-W.W., P.R.d.J, G.H. and M.K. analysed data. J.Z.-R. provided gp130 mutants, S.B.H., J.T.C., B.S.B. and W.J.S. provided human specimens, S.I.G., E.R., Y.M., A.Y., J.Z.-R. and K.-L.G. provided conceptual advice. K.T., L.-W.W. and M.K. wrote the manuscript, with all authors contributing to the writing and providing advice.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Michael Karin.

Extended data

About this article

Publication history





Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.